Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

- Revenues From Continuing Operations Increase 25 Percent to $62.6 Million -

- Conference Call Today at 4:30 p.m. Eastern Time -

INCLINE VILLAGE, Nev., May 7 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2009.

Total revenues from continuing operations for the first quarter of 2009 were $62.6 million, a 25 percent increase from $50.2 million for the same period in 2008. The increase was primarily due to increases in royalty revenues driven by higher product sales of Avastin(R), Herceptin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by MedImmune, Inc.

"We were pleased to begin fulfilling the goal of income distribution to stockholders by paying our first post-spin-off dividend in April, a result of the revenues and profits PDL is generating from royalties on a diversified portfolio of successful products," said John McLaughlin, president and chief executive officer of PDL BioPharma. "Our new and focused strategy seeks to optimize our assets to benefit stockholders without the diversion, expense, and considerable risk of research and development."

Total general and administrative expenses from continuing operations in the first quarter of 2009 were $4.7 million compared with $12.7 million in the first quarter of 2008. The decrease was primarily driven by the Company's reduced cost structure. Significant expense items for the first quarter of 2009 included $1.6 million in legal fees for patent prosecution, patent defense and corporate complia
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer ... to be found at the junctures where ... burgeoning world of nanotechnology, the interfaces between ... prominent, with applications in such high-tech favorites ... Realizing the vast potential of these metal ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as ... its SBIR Phase 2 award from the Army ... comprehensive air purification system that kills all biological ... allergens and organic particulates.  In independent testing sponsored ...
(Date:1/15/2014)... and SAN JOSE, California , ... an international biotechnology company developing antibody-drug conjugates for cancer, ... PhD to its Board of Directors. Dr Reynolds has ... industry, most recently as Chief Medical Officer at Seattle ... at this transformative time for Oxford BioTherapeutics, as the ...
(Date:1/15/2014)... January 15, 2014 A study ... win races on the Formula 1 track could help ... collaboration between McLaren Applied Technologies (MAT), Stowhealth (a GP ... Suffolk is being funded by healthcare provider Simplyhealth. ... to collect data about the on-track performance of Vodafone ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
... 16 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... at the Wells Fargo Securities Healthcare Conference in Boston on ... PT . , , , ... the presentation will be available online from the investor relations page of the ...
... Trans World Alloys (TWA), one of the country,s premier titanium sheet ... joined the company, as its new Chief Operating Officer. ACCORDING TO SANDY SHADROW, ... the metal business in a variety of areas." , ... Ed has attended the University of Baltimore , the ...
Cached Biology Technology:World of lights in the microcosmos 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2Ed Brennan - New C.O.O. of Trans World Alloys 2
(Date:4/16/2014)... and soil processes are to blame for significant baseline ... a study published recently in the Journal of ... samples from all corners of Ohio showed that every ... of concern recommended by the U.S. Environmental Protection Agency. ... authors, who note that regulatory levels typically are set ...
(Date:4/16/2014)... Leo Heim and their colleagues at the University of ... of generating hydrogen using water and formaldehyde. The generation ... it comes to fuel cell technologies. The results of ... water and formaldehyde", have recently been published in the ... the new approach can be used to recycle industrial ...
(Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... 2010) When researchers tested three different labeling agents ... effect the labeling agents had on stem cell phenotype, ... stem cell proliferation depending on the type of contrast ... and Spain tested USPIO (ultra small superparamagnetic iron oxide) ...
... voracious predatory crabs due to global warming could threaten ... published findings. "King crabs are ecologically important ... fisheries," said Dr Sven Thatje, an evolutionary ecologist at ... Science (SOES), which is based at the National Oceanography ...
... to spot prey, vision keeps many animals, including humans, alive. ... is it easier for us to spot movement of small ... things? The complexity of the neural network that supports vision ... and support from the National Science Foundation, Claire Wyart in ...
Cached Biology News:MRI contrast agents change stem cell proliferation 2King crab distributions limited by temperature in the Southern Ocean 2The zebrafish's neural circuit prevents it from biting off more than it can chew 2
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: